Patients w/ propensity to bleed (eg, due to recent trauma or surgery, active or recent GI bleeding, moderate hepatic impairment) or who are at increased risk of trauma. Concomitant administration of medicinal products that may increase the risk of bleeding (eg, NSAIDs, oral anticoagulants &/or fibrinolytics w/in 24 hr); antifibrinolytic therapy (aminocaproic acid or tranexamic acid) &/or recombinant factor VIIa therapy. Discontinue 5 days prior to surgery if to undergo elective surgery & antiplatelet effect is not desired. Patients w/ prior ischaemic stroke. Potential risk for bradyarrhythmia; patients at increased risk of bradycardic events (eg, patients w/o pacemaker w/ sick sinus syndrome, 2nd- or 3rd-degree AV block or bradycardic-related syncope). Discontinue use if new, prolonged or worsened dyspnoea occurs. Central sleep apnoea including Cheyne-Stokes respiration. Promptly treat patient if TTP occurs. False -ve platelet function test results for heparin-induced thrombocytopenia. History of hyperuricaemia or gouty arthritis. Not recommended to be co-administered w/ high maintenance dose of ASA (>300 mg). Avoid premature discontinuation of treatment. Possible dizziness & confusion; observe caution while driving or using machines. Moderate hepatic impairment. Pregnancy. Not recommended during breastfeeding. Childn <18 yr.
Sign Out
